G7 Freedom Constrained Vivacit-E Liners

Multicenter, Prospective Post-Market Clinical Follow-Up Study of the G7® Freedom Constrained Vivacit-E® Liners

The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Freedom Constrained Vivacit-E Acetabular Liners in primary and revision total hip arthroplasty.

Study Overview

• Status: Enrolling by invitation
• Conditions: Rheumatoid Arthritis; Avascular Necrosis; Osteoarthritis, Hip; Femoral Neck Fractures; Dislocation, Hip; Trochanteric Fractures; Non-Union Fracture
• Intervention / Treatment: Device: Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners

Detailed Description

The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Freedom Constrained Vivacit-E Acetabular Liners in primary and revision total hip arthroplasty.

The primary endpoint is defined by the survival of the implant system at 10 years, which is based on removal of the study device and will be determined using the Kaplan-Meier method. The safety of the system will be assessed by monitoring the frequency and incidence of adverse events. Relation of the events to the implant, instrumentation and/or procedure should be specified.

The secondary endpoints are the assessment of performance and clinical benefits by recording patient-reported clinical outcomes measures (PROMs) as well as radiographic outcomes (if available).

The G7 Vivacit-E Freedom Constrained Liner is indicated for use (per IFU) as a component of a total hip prosthesis in primary and revision patients at high risk of dislocation due to a history of prior dislocation, bone loss, joint or soft tissue laxity, neuromuscular disease, or intraoperative instability, and for whom all other options to constrained acetabular components have been considered.

• Study Type: Interventional
• Enrollment (Estimated): 202
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 35205
      • University of Alabama at Birmingham
  • California
    • Los Angeles, California, United States, 90033
      • University of Southern California
  • Florida
    • Gainesville, Florida, United States, 32611
      • University of Florida Board of Trustees
  • New Jersey
    • Livingston, New Jersey, United States, 07039
      • Jersey City Medical Center, Inc
  • Ohio
    • Columbus, Ohio, United States, 43201
      • The Ohio State University
  • Tennessee
    • Knoxville, Tennessee, United States, 37923
      • TOA Research Foundation
  • Texas
    • Houston, Texas, United States, 77030
      • The University of Texas Health Science Center of Houston
    • Plano, Texas, United States, 75075
      • Medical City Plano
  • Utah
    • Salt Lake City, Utah, United States, 84108
      • University of Utah
  • West Virginia
    • Morgantown, West Virginia, United States, 26506
      • West Virginia University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 76 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patient is 18 to 80 years of age, inclusive
• Patient is skeletally mature

• Patient qualifies for unilateral total hip arthroplasty based on physical exam and medical history including at least one of the following:

  • Non-inflammatory degenerative joint disease, including osteoarthritis and avascular necrosis
  • Rheumatoid arthritis
  • High risk for dislocation
  • Undergoing revision hip arthroplasty
  • Correction of functional deformity
  • In need of treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques
• Patient is willing and able to complete scheduled follow-up evaluations as described in the protocol and Informed Consent
• Patient, or the patient's legally authorized representative, has participated in the Informed Consent process and is willing and able to sign an IRB approved informed consent

Exclusion Criteria:

• Patient is septic, has an active infection or has osteomyelitis at the affected joint
• Patient has significant osteoporosis as defined by treating surgeon
• Patient has metabolic disorder(s) which may impair bone formation
• Patient has osteomalacia
• Patient has distant foci of infections which may spread to the implant site
• Patient has rapid joint destruction, marked bone loss or bone resorption on pre-operative radiographs
• Patient underwent contralateral THA within 3 months of planned index procedure or has a contralateral THA planned within 3 months of the index procedure
• Patient is undergoing simultaneous bilateral THA
• Patient has vascular insufficiency, muscular atrophy at the implant site or neuromuscular disease which might jeopardize the outcome of the surgery.
• In the opinion of the investigator, patient has any concomitant disease which is likely to jeopardize the functioning or success of the implant
• Patient is known to be pregnant

• The patient is in the vulnerable population group, such as

  • a prisoner
  • a known alcohol or drug abuser
  • mentally incompetent or unable to understand what participation in this study entails

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Total Hip Arthroplasty Treatment Group; This study will enroll (implant) up to 202 hips in total according to the IFU and surgical technique. Of these, up to 135 will be revision hips and up to 67 will be primary hips. This is a dual cohort study (primary and revision); each subject will receive the G7 Acetabular System with the Freedom Constrained Vivacit-E bearing. To minimize potential bias and to maximize our ability to assess inter-site differences, each study site will target up to 27 primary hip arthroplasties and up to 54 revision hip arthroplasties (not exceed 81 implanted hips or 40% of total study population). Each site is encouraged to enroll (implant) both primary and revision subjects.

Device: Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners; Primary and/or Revision total hip arthroplasty with the G7 Freedom Constrained Vivacit-E Liners

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Survival of the study device	Survival (whether or not it is still implanted in the subject) determined using Kaplan Meier method.	10 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of treatment-emergent Adverse Events (safety)	Safety is assessed by monitoring the frequency and incidence of all adverse events, with particular focus on those that may be related to the study device.	10 years
Pain and Functional Performance - Modified Harris Hip Score	The Harris Hip Score evaluates hip function, pain, mobility and daily activity impairment after hip replacement surgery. The ten items in the Harris hip score consist of answer choices, awarded a number of points. There are four domains evaluated, as follows: Pain - 1 item which scores between 0 and 44;; Function - 7 items, scores are between 0 and 47;; Deformity - 1 item which scores either 0 or 4;; Range of motion - 1 item which scores between 0 and 5. The overall score varies between 0 and 100, where scores closer to 0 are suggestive of impaired hip function and scores closer to 100 indicate positive outcome. There are four categories of hip function status: <70: poor hip status;; 70 - 79: fair hip status;; 80 - 89: good hip status;; 90 - 100: excellent hip status.	10 years
Pain and Functional Performance - Oxford Hip Score	"The Oxford Hip Score is patient-reported outcome instrument which contains 12 questions on activities of daily living that assess function and residual pain in patients undergoing total hip replacement surgery. Grading the Oxford Hip Score 0 to 19-May indicate severe hip arthritis... 20 to 29-May indicate moderate to severe hip arthritis... 30 to 39-May indicate mild to moderate hip arthritis... 40 to 48-May indicate satisfactory joint function..." Oxford Hip Score. (n.d.) Segen's Medical Dictionary. (2011). Retrieved August 19 2022 from https://medical-dictionary.thefreedictionary.com/Oxford+Hip+Score Each question is scored from 0 to 4 with 4 being the best outcome. This method, when summed, produces overall scores running from 0 to 48 with 48 being the best outcome. The overall score is reached by simply summing the scores received for individual questions. This results in a continuous score ranging from 0 (most severe symptoms) to 48 (least symptoms).	10 years
Euroqol Patient Quality of life measured at 2 years follow-up (EQ-5D-5L)	The EuroQol five dimensions questionnaire (EQ-5D-5L) is a five dimensional self-assessment that is comprised of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. These five dimensions can be used to index a subject's health utility on a scale of 0 to 1, where 0 is death and 1 is perfect health. The scoring rule for EQ-5D permits scores less than 0, implying that some health states may be worse than death. Note: no VAS measures will be obtained if completed by phone interview.	10 Years
Radiographic Performance evaluating radiolucency at 5 years follow-up	X-rays will be evaluated for radiolucency lines to show the number of subjects with radiolucency. Radiolucency refers to structures that are less dense and permit the x-ray beam to pass through them. Radiolucent structures appear dark or black in the radiographic image.	5 Years
Radiographic Performance evaluating osteolysis at 5 years follow-up	X-rays will be evaluated for osteolysis to show the number of subjects with osteolysis. Osteolysis is a progressive condition where bone tissue is destroyed. In this process, bones lose minerals (mostly calcium), softens, degenerates and become weaker.	5 Years
Radiographic Performance evaluating atrophy/hypertrophy at 5 years follow-up	X-rays will be evaluated for muscular atrophy/hypertrophy. An increase in total mass of a muscle is referred to as as hypertrophy, whereas a decrease in total mass of a muscle is referred to as atrophy.	5 Years
Radiographic Performance evaluating component migration at 5 years follow-up	X-rays will be evaluated for component migration to show the number of subjects with migration. Component migration refers to the presence of the device component gradually moving anteriorly, posteriorly, superiorly, or inferiorly in relation to original placement.	5 Years
Radiographic Performance evaluating device fracture at 5 years follow-up	Radiographs will be evaluated (up to 5 years) for evidence of device fracture.	5 Years
Radiographic Performance evaluating heterotopic ossification at 5 years follow-up	X-rays will be evaluated for heterotopic ossification to show the number of subjects with heterotopic ossification. Heterotopic ossification refers to the presence of bone in soft tissue where bone normally does not exist (extraskeletal bone).	5 Years

Collaborators and Investigators

• Sponsor: Zimmer Biomet
• Investigators: Study Director: Hillary Overholser, Zimmer Biomet

Study record dates

Study Major Dates

• Study Start (Actual): May 8, 2023
• Primary Completion (Estimated): December 1, 2037
• Study Completion (Estimated): December 1, 2038

Study Registration Dates

• First Submitted: October 10, 2022
• First Submitted That Met QC Criteria: October 17, 2022
• First Posted (Actual): October 20, 2022

Study Record Updates

• Last Update Posted (Estimated): October 20, 2025
• Last Update Submitted That Met QC Criteria: October 16, 2025
• Last Verified: October 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Bone Diseases; Musculoskeletal Diseases; Wounds and Injuries; Pathologic Processes; Arthritis; Joint Diseases; Rheumatic Diseases; Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases; Leg Injuries; Necrosis; Fractures, Bone; Osteoarthritis; Femoral Fractures; Hip Injuries; Joint Dislocations; Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases; Fractures, Ununited; Arthritis, Rheumatoid; Hip Fractures; Osteoarthritis, Hip; Femoral Neck Fractures; Osteonecrosis; Hip Dislocation; Surgical Procedures, Operative; Arthroplasty, Replacement; Arthroplasty; Orthopedic Procedures; Plastic Surgery Procedures; Prosthesis Implantation; Arthroplasty, Replacement, Hip
• Other Study ID Numbers: CMG2021-36H

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes